Eli Lilly said revenue for Q3 2024 rose 20% to $11,439.1 million, and reported EPS was $1.07 and non-GAAP EPS was $1.18, both including $3.08 of acquired IPR&D charges.

1. 01

   Eli Lilly said revenue for Q3 2024 rose 20% to $11,439.1 million, and reported EPS was $1.07 and non-GAAP EPS was $1.18, both including $3.08 of acquired IPR&D charges.

2. 02

   The company said that excluding revenue of $1.42 billion from the sale of rights to the olanzapine (Zyprexa) portfolio in Q3 2023, Q3 2024 revenue rose 42%. It said Mounjaro revenue in Q3 2024 was $3.11 billion, and U.S. Zepbound revenue was $1.26 billion.

3. 03

   The company said it recognized acquired IPR&D charges of $2.83 billion in Q3 2024, primarily related to the acquisition of Morphic Holding, Inc., compared with $2.98 billion in Q3 2023.

4. 04

   The company updated its full-year 2024 revenue guidance to $45.4 to $46.0 billion from $45.4 to $46.6 billion, and changed its reported EPS guidance to $12.05 to $12.55 from $15.10 to $15.60.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.